Roche to acquire Poseida Therapeutics in deal worth up to $1.5 billion
MLex Summary: Switzerland-based Roche is acquiring United States-based partner Poseida Therapeutics, including its cell therapy candidates and related platform technologies, in a deal worth up to $1.5 billion. The companies, which...To view the full article, register now.
Already a subscriber? Click here to view full article